uniQure (NASDAQ:QURE) Trading Down 4.4% - Here's Why

Key Points

• uniQure shares fell 4.4% to about $44.18 despite the company submitting U.S. and U.K. applications for accelerated approval of AMT-130, its Huntington’s disease gene therapy.
• The FDA filing could qualify for Priority Review, while three-year Phase I/II data showed slower disease progression; however, regulators still must accept the applications and may require costly confirmatory studies.
• Wall Street remains broadly positive, with a “Moderate Buy” consensus and an average price target of $65, but recent insider selling and uniQure’s larger-than-expected quarterly loss add caution.

uniQure N.V. (NASDAQ:QURE - Get Free Report)'s stock price was down 4.4% on Thursday . The stock traded as low as $44.17 and last traded at $44.1810. Approximately 452,545 shares traded hands during trading, a decline of 81% from the average session volume of 2,365,216 shares. The stock had previously closed at $46.23.

Key uniQure News

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: uniQure submitted a Biologics License Application (BLA) to the FDA seeking accelerated approval for AMT-130, a major step toward commercialization. The company also filed a Marketing Authorisation Application with the U.K. MHRA, broadening its potential market opportunity. uniQure Announces Submission of Biologics License Application
• Positive Sentiment: The FDA filing is eligible for Priority Review, which could reduce the review period to six months after the agency’s initial 60-day filing review—although Priority Review has been requested, not yet granted. AMT-130 also has FDA Breakthrough Therapy, RMAT and Fast Track designations. uniQure seeks U.S. approval for Huntington's gene therapy
• Positive Sentiment: The applications rely on three-year Phase I/II data indicating slower disease progression versus an external natural-history control. uniQure expects to present four-year data before the end of the third quarter, providing another potential catalyst. uniQure, after setbacks, seeks FDA approval
• Positive Sentiment: William Blair resumed coverage with an Outperform rating and a $73 fair-value estimate, adding Wall Street support following the regulatory update. uniQure FDA filing and analyst commentary
• Neutral Sentiment: The regulatory submission follows a significant FDA shift from previously seeking a larger randomized study to accepting an accelerated-approval filing, creating both substantial upside potential and elevated binary-event volatility.
• Negative Sentiment: The FDA and U.K. regulators must still accept or validate the applications and could determine that the Phase I/II evidence is insufficient. Accelerated approval, if granted, may also require costly confirmatory studies.
• Negative Sentiment: Reported insider activity shows repeated sales and no purchases over the past six months, which may temper investor confidence after the recent rally.

Wall Street Analysts Forecast Growth

QURE has been the topic of several recent analyst reports. Barclays reduced their price target on shares of uniQure from $65.00 to $60.00 and set an "overweight" rating on the stock in a research note on Thursday, July 30th. Wells Fargo & Company raised their target price on shares of uniQure from $60.00 to $75.00 and gave the stock an "overweight" rating in a research report on Thursday, July 30th. William Blair began coverage on uniQure in a report on Wednesday. They issued an "outperform" rating for the company. The Goldman Sachs Group raised their price objective on uniQure from $14.00 to $46.00 and gave the stock a "neutral" rating in a report on Thursday, June 18th. Finally, Cantor Fitzgerald raised uniQure from a "neutral" rating to an "overweight" rating and set a $61.00 target price for the company in a research report on Wednesday, June 17th. Fourteen analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $65.00.

uniQure Price Performance

The stock has a fifty day moving average price of $44.45 and a 200-day moving average price of $30.07. The firm has a market capitalization of $3.12 billion, a PE ratio of -11.17 and a beta of 0.94. The company has a debt-to-equity ratio of 0.15, a quick ratio of 10.01 and a current ratio of 10.01.

uniQure (NASDAQ:QURE - Get Free Report) last issued its quarterly earnings data on Wednesday, July 29th. The biotechnology company reported ($1.22) earnings per share for the quarter, missing analysts' consensus estimates of ($0.82) by ($0.40). The company had revenue of $5.84 million for the quarter, compared to analysts' expectations of $5.45 million. uniQure had a negative return on equity of 111.96% and a negative net margin of 1,350.73%.During the same quarter last year, the company earned ($0.69) earnings per share. Sell-side analysts forecast that uniQure N.V. will post -3.74 EPS for the current fiscal year.

Insider Activity

In other uniQure news, insider Kylie O'keefe sold 15,936 shares of uniQure stock in a transaction on Thursday, June 11th. The shares were sold at an average price of $27.06, for a total value of $431,228.16. Following the transaction, the insider directly owned 108,864 shares of the company's stock, valued at approximately $2,945,859.84. The trade was a 12.77% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Walid Abi-Saab sold 30,000 shares of the company's stock in a transaction on Tuesday, June 30th. The stock was sold at an average price of $46.42, for a total value of $1,392,600.00. Following the transaction, the insider directly owned 148,235 shares in the company, valued at approximately $6,881,068.70. The trade was a 16.83% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 385,584 shares of company stock worth $16,737,722 over the last 90 days. 4.65% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Woodline Partners LP raised its stake in uniQure by 25.0% in the first quarter. Woodline Partners LP now owns 175,806 shares of the biotechnology company's stock valued at $1,864,000 after buying an additional 35,175 shares during the last quarter. Legal & General Group Plc purchased a new stake in shares of uniQure during the second quarter worth about $497,000. Marshall Wace LLP increased its holdings in shares of uniQure by 276.5% during the second quarter. Marshall Wace LLP now owns 222,979 shares of the biotechnology company's stock valued at $3,108,000 after acquiring an additional 163,749 shares in the last quarter. California State Teachers Retirement System acquired a new position in shares of uniQure during the second quarter valued at about $540,000. Finally, Ameriprise Financial Inc. raised its position in shares of uniQure by 38.6% in the 2nd quarter. Ameriprise Financial Inc. now owns 761,948 shares of the biotechnology company's stock valued at $10,622,000 after purchasing an additional 212,218 shares during the last quarter. 78.83% of the stock is currently owned by hedge funds and other institutional investors.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure's pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington's disease, and Parkinson's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source